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A Two-Step Activation Mechanism
of MALT1 ParacaspaseThe paracaspase MALT1 plays a central signaling
role in the response to activation of a growing list of
receptors found on immune cells and other cell
types. However, the best known is its role in NF-κB
signaling during antigen-receptor-induced lympho-
cyte activation and lymphomagenesis.1 MALT1
was long believed to act solely as a scaffolding
protein, but 3 years ago, we and Margot Thome's
group revealed that MALT1 has functionally
important proteolytic activity and holds promise
as a therapeutic target in neoplastic and inﬂamma-
tory disorders associated with deregulated NF-κB
signaling.2,3 MALT1 proteolytic activity is mediated
by its caspase-like domain, but unlike caspases,
which speciﬁcally cleave their substrates after
aspartic acid, MALT1 cleaves its substrates after
arginine.
Activation of MALT1 and determination of its
substrate activity are not understood. Very recent-
ly, the structure of the human MALT1 caspase-like
domain in complex with a peptide inhibitor was
published,4 showing that the paracaspase domain
adopts a fold that is nearly identical with that of
classic caspases. In this issue, Wiesmann et al. go a
step further by reporting the crystal structure of
the MALT1 caspase-like domain in its free and
substrate-bound forms and providing further
biochemical and structural insight into the mech-
anism of MALT1 activation.5 The N-terminal
death domain (DD) of MALT1 is followed by
two immunoglobulin (Ig)-like domains, a caspase-
like domain, another Ig-like domain, and 100 C-
terminal residues lacking any discernible second-
ary structure. According to Wiesmann et al.,
MALT1Casp-Ig3 is the minimal unit of activity, as
shown by several C-terminal deletions of full-
length MALT1, but is in itself not active and
requires dimerization to gain activity. The require-
ment for dimerization in MALT1 proteolytic
activity is further supported by the observation
that MALT1Casp-Ig3 forms covalent adducts with
the peptide inhibitor z-VRPR-fmk, which, in turn,
stimulates the formation of stable dimers that can0022-2836 © 2012 Elsevier Ltd. Open access under CC BY-NC-ND licenbe isolated by chromatography. Despite the weak
primary sequence similarity to caspases, the
caspase-like domain of MALT1 folds into a
structure highly similar to caspases. In its sub-
strate-free form, the structure of the MALT1
caspase-like domain strongly resembles inactive
caspase-9, but binding to the z-VRPR-fmk sub-
strate causes the caspase-like domain to adopt a
shape resembling that of active initiator caspases.
Site-speciﬁc mutation in the caspase-like domain at
the dimer interface caused complete loss of
proteolytic activity. These data collectively indicate
that MALT1 follows the general activation mech-
anism of initiator caspases, which depends on
dimerization. Unlike caspases, however, the active
andmature form of the paracaspase domain remains
a single uncleaved polypeptide.
The structure ofMALT1Casp-Ig3 further shows that,
along with the caspase-like domain, the Ig3 domain
also changes conformation upon binding with a
peptide inhibitor, indicating that substrate binding
causes substantial structural reorganization. In the
substrate-free state, the Ig3 domain interacts with the
caspase-like domain via several hydrophobic resi-
dues, stabilizing or forcing the structure to adopt an
inactive conformation. However, upon substrate
binding, the Ig3 domain twists and releases the
caspase-like domain. Despite very weak primary
sequence similarity, the Ig3-like domain of MALT1
folds into a structure highly similar to the γ-adaptin
ear domain family,4,5 which is involved in protein–
protein interaction by binding a relatively speciﬁc
sequence stretch.6 Thus, activation of MALT1 seems
to require a two-step process: ﬁrst, the caspase-like
domain is dimerized, and upon substrate binding, it
is released from Ig3-mediated autoinhibition.
Recently published structures of MALT1DD-Ig1-Ig2
and fragments thereof indicate that Ig1 and Ig2
of MALT1 might contribute to MALT1 homo-
dimerization.7 It will be interesting to see how
the ﬁndings of Wiesmann et al. on dimerization-
dependent activation will ﬁt in a comprehensive
model in which the domains upstream of the caspase-se.
2 Two-Step Activation Mechanism of MALT1like domain are also taken into account and,
ultimately, how MALT1 activation is managed in a
signaling context. It will be worthwhile to analyze the
ability of hybrid dimers of MALT1 and caspase-8, as
previously suggested by co-immunoprecipitation,8 to
adopt an active conformation.
Determination of the optimal substrate cleavage
site by tetrapeptide substrate screening showed
that a hydrophobic residue in P4 and arginine in P1
are required, and that a small, uncharged residue in
P2 and P1′ is preferred.5 These ﬁndings parallel
those in a recent independent study.9 Binding of
z-VRPR-fmk in the catalytic pocket of both human
and mouse MALT1Casp-Ig3 further revealed that the
P1 arginine binds in the S1 pocket and that it is
unlikely that lysine is accepted as a P1 residue,
unlike the related metacaspases, which accept both
lysine and arginine. The z-VRPR-fmk-bound struc-
ture also showed that P4 valine is bound by a
hydrophobic pocket, but a P4 leucine is many
times more active than a P4 valine, consistent with
the previous observation that the Arabidopsis
metacaspase-9-optimized z-VRPR-fmk is a poor
MALT1 inhibitor.10,11 The optimal substrate cleav-
age site obtained by tetrapeptide substrate screening
ﬁts most of the known physiological protein
substrates,2,3,11–13 except for A20, whose tetrapep-
tide cleavage sequence GASR is a poor substrate.
However, as shown by Hachmann et al.,9 the P5
position also contributes to cleavage site speciﬁcity.
In agreement, we observed that mutation of the P5
leucine of A20 into a glycine prevents its cleavage by
MALT1 (unpublished results), indicating that P5 can
cover for the hydrophobic dependency in the P4
position in some physiological substrates. This also
ﬁts with structural data showing a wide hydropho-
bic pocket binding P4/P5. It seems that MALT1
tolerates considerable variation in the primary
sequence of the cleavage site. However, a large
substrate, such as CYLD, is cleaved only at a single
site.9,11 Therefore, future studies should investigate
how selectivity is obtained. Hachmann et al.
suggested that additional activity and speciﬁcity
may be determined by an exosite.9 The results
Wiesmann et al. reported in this issue indicate that
the Ig3 domain is involved in substrate-binding-
induced structural reorganization and activation of
MALT1.5 The autoinhibitory properties of the Ig3
domain and its potential speciﬁc amino acid binding
properties could indicate that this domain is a
MALT1 regulatory exosite that determines speciﬁc
cleavage sites in physiological substrates. We
expect that knowledge of the MALT1 structure
and the preferred substrate cleavage site will
accelerate the discovery of new physiological sub-strates and the development of more potent
MALT1 inhibitors for therapeutic application.References
1. Staal, J., Bekaert, T. & Beyaert, R. (2011). Regulation of
NF-κB signaling by caspases and MALT1 paracas-
pase. Cell Res. 21, 40–54.
2. Coornaert, B., Baens, M., Heyninck, K., Bekaert, T.,
Haegman, M., Staal, J. et al. (2008). T cell antigen
receptor stimulation induces MALT1 paracaspase-
mediated cleavage of the NF-κB inhibitor A20. Nat.
Immunol. 9, 263–271.
3. Rebeaud, F., Hailfinger, S., Posevitz-Fejfar, A.,
Tapernoux, M., Moser, R., Rueda, D. et al. (2008).
The proteolytic activity of the paracaspase MALT1 is
key in T cell activation. Nat. Immunol. 9, 272–281.
4. Yu, J. W., Jeffrey, P. D., Ha, J. Y., Yang, X. & Shi, Y.
(2011). Crystal structure of the mucosa-associated
lymphoid tissue lymphoma translocation 1 (MALT1)
paracaspase region. Proc. Natl Acad. Sci. USA, 108,
21004–21009.
5. Wiesmann, C., Leder, L., Blank, J., Bernardi, A.,
Melkko, S., Decock, A. et al. (2012). Structural de-
terminants of MALT1 protease activity. J. Mol. Biol.
419, 4–21.
6. Miller, G. J., Mattera, R., Bonifacino, J. S. & Hurley,
J. H. (2003). Recognition of accessory protein motifs
by the gamma-adaptin ear domain of GGA3. Nat.
Struct. Biol. 10, 599–606.
7. Qiu, L. & Dhe-Paganon, S. (2011). Oligomeric struc-
ture of the MALT1 tandem Ig-like domains. PLoS
ONE, 6, e23220.
8. Kawadler, H., Gantz, M. A., Riley, J. L. & Yang, X.
(2008). The paracaspase MALT1 controls caspase-
8 activation during lymphocyte proliferation. Mol.
Cell, 31, 415–421.
9. Hachmann, J., Snipas, S. J., van Raam, B. J., Cancino,
E. M., Houlihan, E. J., Poreba, M. et al. (2012).
Mechanism and specificity of the human paracaspase
MALT1. Biochem. J. 443, 287–295.
10. Vercammen, D., Belenghi, B., van de Cotte, B.,
Beunens, T., Gavigan, J. A., De Rycke, R. et al.
(2006). Serpin1 of Arabidopsis thaliana is a suicide
inhibitor for metacaspase 9. J. Mol. Biol. 364,
625–636.
11. Staal, J., Driege, Y., Bekaert, T., Demeyer, A., Muyllaert,
D., Van Damme, P. et al. (2011). T-cell receptor-induced
JNK activation requires proteolytic inactivation of
CYLD by MALT1. EMBO J. 30, 1742–1752.
12. Hailfinger, S., Nogai, H., Pelzer, C., Jaworski, M.,
Cabalzar, K., Charton, J. E. et al. (2011). Malt1-
dependent RelB cleavage promotes canonical NF-κB
activation in lymphocytes and lymphoma cell lines.
Proc. Natl Acad. Sci. USA, 108, 14596–14601.
13. Rosebeck, S., Madden, L., Jin, X., Gu, S., Apel, I. J.,
Appert, A. et al. (2011). Cleavage of NIK by the API2-
MALT1 fusion oncoprotein leads to noncanonical
NF-κB activation. Science, 331, 468–472.
3Two-Step Activation Mechanism of MALT1Jens Staal
Rudi Beyaert*
Department of Biomedical Molecular Biology,
Unit of Molecular Signal Transduction in Inflammation,
Ghent University, Belgium
Department for Molecular Biomedical Research,
VIB, Ghent, Belgium
*Corresponding author. Department for Molecular
Biomedical Research, VIB,
Technologiepark 927,
B-9052 Ghent (Zwijnaarde), Belgium.
E-mail address: rudi.beyaert@dmbr.vib-UGent.be.
